A Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3
Study of the Oral Fxla Inhibitor Asundexian (Bay 2433334) for the Secondary Prevention of Ischemic
Sponsored by Bayer Healthcare Pharmaceuticals Incorporated
Phase 3 study to investigate the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) compared with placebo in participants after an acute non-cardioembolic ischemic stroke or high-risk TIA